DB
RUBY

Dmitry Balyasny’s Rubius Therapeutics, Inc RUBY Stock Holding History

Dmitry Balyasny’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,429
Closed -$13K – 3406
2022
Q2 		$13K Buy
+15,429
New +$25.9K ﹤0.01% 2554

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Dmitry Balyasny's RUBY Position: Q3 2022 in Review

Dmitry Balyasny sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2022, closing a stake of 15,429 shares — an estimated $13K sold.

Dmitry Balyasny first reported a position in RUBY in Q2 2022 and held it in 1 quarter. The position peaked at $13K in Q2 2022. 62 funds tracked by Wall St. Rank hold RUBY as of Q3 2022.

  • Dmitry Balyasny reported no remaining Rubius Therapeutics, Inc position as of Q3 2022 after selling out during the quarter.
  • Dmitry Balyasny sold 15,429 Rubius Therapeutics, Inc shares in Q3 2022, an estimated $13K.
  • Dmitry Balyasny first reported a position in Rubius Therapeutics, Inc in Q2 2022 and held it in 1 quarter.
  • Dmitry Balyasny's Rubius Therapeutics, Inc position peaked at $13K in Q2 2022.
  • 62 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.